Lipidoses: Clinical Trials

16 trials for Lipidoses, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

16 terminated. 16 Phase 2, 7 Phase 1, 2 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 216Terminated 16
Phase 17Terminated 7
Phase 32Terminated 2

Follow Lipidoses: new trials by email Literature Review of Lipidoses trials Research Report on Lipidoses

Trials (filtered) newest first · largest first

All 16 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Safety and Efficacy Study of LYS-GM101 Gene Therapy in Patients With GM1 Gangliosidosis
LYS-GM101 - GM1 Gangliosidosis
Phase 1 / Phase 2TerminatedLYSOGENE52021-05-112023-06-09
A Long Term Follow-Up Study of Fabry Disease Subjects Treated With FLT190
FLT190 - Fabry Disease, Lysosomal Storage Diseases
Phase 1 / Phase 2TerminatedSpur Therapeutics32020-09-082026-09-03
Combined Intrathecal and Intravenous VTS-270 Therapy for Liver and Neurological Disease Associated With Niemann-Pick Disease, Type C1
VTS-270 - Niemann-Pick Disease, Type C1
Phase 1 / Phase 2TerminatedEunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)22020-01-062022-08-30
Open-label Study of VTS-270 in Participants With Neurologic Manifestations of Niemann-Pick Type C1
VTS-270 - Niemann-Pick Disease, Type C
Phase 2 / Phase 3TerminatedMandos LLC22019-12-022023-12-26
A Fabry Disease Gene Therapy Study
FLT190 - Fabry Disease, Lysosomal Storage Diseases
Phase 1 / Phase 2TerminatedSpur Therapeutics32019-07-082026-09-03
Lentiviral Vector Gene Therapy - The Guard1 Trial of AVR-RD-02 for Subjects With Type 1 Gaucher Disease
AVR-RD-02 - Gaucher Disease
Phase 1 / Phase 2TerminatedAVROBIO82019-05-302024-01-18
Study of Arimoclomol in Patients Diagnosed With Gaucher Disease Type 1 or 3
Arimoclomol, Placebo oral capsule - Gaucher Disease, Type 1, Gaucher Disease, Type 3
Phase 2TerminatedZevraDenmark392018-06-062023-01-11
Open Label, Study Of Efficacy and Safety Of AVR-RD-01 for Treatment-Naive Subjects With Classic Fabry Disease
AVR-RD-01 - Fabry Disease
Phase 1 / Phase 2TerminatedAVROBIO152018-02-212024-01-05
Adrabetadex to Treat Niemann-Pick Type C1 (NPC1) Disease
Adrabetadex - Niemann-Pick Disease, Type C
Phase 2 / Phase 3TerminatedMandos LLC662015-12-232023-08-29
Clinical Study In Infants With Rapidly Progressive Lysosomal Acid Lipase Deficiency
Sebelipase Alfa - Lysosomal Acid Lipase Deficiency
Phase 2TerminatedAlexion Pharmaceuticals, Inc.102014-06-062019-11-18
Phase I/II Pilot Study of Mixed Chimerism to Treat Inherited Metabolic Disorders
hematopoietic stem cell infusion - Hurler Syndrome (MPS I), Hurler-Scheie Syndrome
Phase 1 / Phase 2TerminatedTalaris Therapeutics Inc.32011-04-012023-04-12
Hematopoietic Stem Cell Transplantation (HCT) for Inborn Errors of Metabolism
Stem Cell Transplantation, Cyclophosphamide, Campath-1H - Hurler's Syndrome, Maroteaux-Lamy Syndrome
Phase 2TerminatedMasonic Cancer Center, University of Minnesota182008-03-012017-12-28
Open-Label Extension Study of Recombinant Human Arylsulfatase A (HGT-1111) in Late Infantile MLD
HGT-1111 - Late Infantile Metachromatic Leukodystrophy
Phase 2TerminatedShire112008-02-202021-06-08
Open-label Long-term Safety Study of AT1001 (Migalastat Hydrochloride) in Participants With Fabry Disease Who Have Completed a Previous AT1001 Study
migalastat HCl - Fabry Disease
Phase 2TerminatedAmicus Therapeutics232007-09-172018-10-03
Severe Renal Disease Study in Fabry Patients Treated With Fabrazyme
Fabrazyme (agalsidase beta) - Fabry Disease, Chronic Kidney Disease, Stage IV (Severe)
Phase 2TerminatedGenzyme, a Sanofi Company202002-12-012015-04-07
Effect of Glycerol Trierucate on Clinical Course of Adrenoleukodystrophy
glyceryl trierucate/glyceryl trioleate - Adrenoleukodystrophy
Phase 2TerminatedHugo W. Moser Research Institute at Kennedy Krieger, Inc.1261998-04-012020-10-23

Narrower conditions

Fabry Disease (5)  ·  Lysosomal Storage Diseases (4)  ·  Niemann-Pick Disease, Type C (4)  ·  Leukodystrophy, Metachromatic (3)  ·  Adrenoleukodystrophy (2)  ·  Gaucher Disease (2)  ·  Leukodystrophy, Globoid Cell (2)  ·  Metabolism, Inborn Errors (2)  ·  Mucopolysaccharidosis I (2)  ·  Niemann-Pick Diseases (2)  ·  Sphingolipidoses (2)  ·  Wolman Disease (2)  ·  alpha-Mannosidosis (2)  ·  Aspartylglucosaminuria (1)  ·  Chanarin-Dorfman Syndrome (1)

Broader conditions

Brain Diseases (16)  ·  Brain Diseases, Metabolic (16)  ·  Brain Diseases, Metabolic, Inborn (16)  ·  Central Nervous System Diseases (16)  ·  Congenital, Hereditary, and Neonatal Diseases and Abnormalities (16)  ·  Genetic Diseases, Inborn (16)  ·  Lipid Metabolism Disorders (16)  ·  Lipid Metabolism, Inborn Errors (16)  ·  Lysosomal Storage Diseases, Nervous System (16)  ·  Metabolic Diseases (16)  ·  Nervous System Diseases (16)  ·  Nutritional and Metabolic Diseases (16)  ·  Metabolism, Inborn Errors (14)  ·  Sphingolipidoses (14)

Interventions

2-Hydroxypropyl-beta-cyclodextrin (2)  ·  Cyclodextrins (2)  ·  Stem Cell Transplantation (2)  ·  Alemtuzumab (1)  ·  Bone Marrow Transplantation (1)  ·  Busulfan (1)  ·  Cyclophosphamide (1)  ·  Lorenzo's oil (1)  ·  Sebelipase alfa (1)  ·  Triolein (1)  ·  agalsidase beta (1)  ·  arimoclomol (1)  ·  larazotide acetate (1)  ·  migalastat (1)  ·  trierucate (1)

Sponsors

AVROBIO (2)  ·  Mandos LLC (2)  ·  Spur Therapeutics (2)  ·  Alexion Pharmaceuticals, Inc. (1)  ·  Amicus Therapeutics (1)  ·  Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) (1)  ·  Genzyme, a Sanofi Company (1)  ·  Hugo W. Moser Research Institute at Kennedy Krieger, Inc. (1)  ·  LYSOGENE (1)  ·  Masonic Cancer Center, University of Minnesota (1)  ·  Shire (1)  ·  Talaris Therapeutics Inc. (1)  ·  ZevraDenmark (1)

Countries

United States (12)  ·  United Kingdom (6)  ·  Australia (3)  ·  France (3)  ·  Germany (3)  ·  Brazil (2)  ·  Canada (2)  ·  Italy (2)  ·  Austria (1)  ·  Costa Rica (1)  ·  Denmark (1)  ·  Finland (1)  ·  India (1)  ·  New Zealand (1)  ·  Norway (1)

Top investigators

Aabha Nagral, MD (1)  ·  Forbes D Porter, M.D. (1)  ·  Gerald V Raymond, M.D. (1)  ·  Inderpal Panesar, MRPharmS (1)  ·  Milena Veselinovic, MD (1)  ·  Paul Orchard, MD (1)  ·  Suzanne T Ildstad, MD (1)

Results publications

PMID 21586746, PMID 33332761, PMID 36631545, PMID 37624739

NIH funding

2008 (1), 2015 (1)